Centogene Valuation

Is 39K undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 39K when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 39K's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 39K's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 39K?

Key metric: As 39K is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 39K. This is calculated by dividing 39K's market cap by their current revenue.
What is 39K's PS Ratio?
PS Ratio	0.06x
Sales	€48.54m
Market Cap	€3.06m

39K key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.4x
Enterprise Value/EBITDA	-2.1x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 39K's PS Ratio compare to its peers?

The above table shows the PS ratio for 39K vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	0.5x
HT6 Learning 2 Sleep L2S	0.3x	n/a	€85.9k
V3V VITA 34	0.9x	3.1%	€72.5m
EIF MedNation	0.1x	n/a	€4.4m
UOM AS Latvijas Juras medicinas centrs	0.5x	n/a	€5.4m
39K Centogene	0.06x	n/a	€3.2m

Price-To-Sales vs Peers: 39K is good value based on its Price-To-Sales Ratio (0.1x) compared to the peer average (0.5x).

Price to Sales Ratio vs Industry

How does 39K's PS Ratio compare vs other companies in the DE Healthcare Industry?

2 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	0.6x	3.8%
39K Centogene	0.06x	n/a	US$3.19m
TLIK Arzneiwerk VIDA	0.08x	n/a	US$4.67m

No more companies available in this PS range

2 Companies		Estimated Growth	Market Cap
Industry Avg.	0.6x	27.7%
39K Centogene	0.06x	n/a	US$3.19m

No more companies

Price-To-Sales vs Industry: 39K is good value based on its Price-To-Sales Ratio (0.1x) compared to the European Healthcare industry average (0.6x).

Price to Sales Ratio vs Fair Ratio

What is 39K's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

39K PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.06x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 39K's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

LNA Santé

€244.4m

Engages in the management and operation of health establishments.

2N3

€23.25

-6.1%

16.0%

Shandong Weigao Group Medical Polymer

HK$20.1b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.52

-1.0%

-38.8%

Top Glove Corporation Bhd

RM 7.8b

An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.

5OU

RM 0.98

0.5%

-82.5%